Sanofi shifts focus to internal R&D as it preps an end to a stunningly effective Regeneron alliance
One of the biggest, most productive partnerships in antibody development is coming to a close.
Regeneron noted in its Q2 report Thursday that its long-running alliance with Sanofi on antibody development will expire — as scheduled — at the end of this year. And the pharma giant says it’s ready to shift to a closer focus on its internal pipeline, which has been a sore disappointment for years now.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
